Skip to main content
. 2010 Mar 16;102(7):1137–1144. doi: 10.1038/sj.bjc.6605612

Figure 3.

Figure 3

Patients with mitogen-activated protein kinase phosphatase-1 (MKP-1) overexpression show shorter median time to progression (TTP) than MKP-1 non-overexpressing patients in KRAS wild-type colon cancer patients treated with cetuximab (13 vs 32 weeks, P=0.009).